ABSI
Absci Corporation NASDAQ Listed Jul 22, 2021$7.41
+3.20%
vs $7.18
Mkt Cap $1.2B
52w Low $2.24
87.2% of range
52w High $8.17
50d MA $5.29
200d MA $3.71
P/E (TTM)
-8.8x
EV/EBITDA
—
P/B
5.3x
Debt/Equity
0.0x
ROE
-60.8%
P/FCF
-10.8x
RSI (14)
55.90
ATR (14)
$0.71
Beta
2.01
50d MA
$5.29
200d MA
$3.71
Avg Volume
5.0M
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
CIK (SEC)
Phone
360 949 1041
18105 SE Mill Plain Boulevard · Vancouver, WA 98683 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.20 | -0.19 | +5.0% | 5.75 | -12.3% | +2.6% | -2.0% | -7.3% | -1.1% | +4.5% | — |
| Mar 24, 2026 | AMC | -0.16 | -0.23 | -43.8% | 3.01 | -3.7% | -3.0% | -1.4% | -3.5% | -0.7% | +8.7% | — |
| Nov 12, 2025 | AMC | -0.19 | -0.20 | -5.3% | 3.40 | -12.4% | -22.4% | +6.8% | +1.4% | -0.7% | +0.7% | — |
| Aug 12, 2025 | AMC | -0.19 | -0.24 | -26.3% | 2.97 | -4.4% | +5.1% | -3.8% | -2.3% | -3.4% | -7.4% | — |
| May 13, 2025 | AMC | -0.23 | -0.21 | +8.7% | 2.96 | +22.0% | -1.7% | +1.7% | -2.7% | -3.8% | +0.7% | — |
| Mar 18, 2025 | AMC | -0.22 | -0.25 | -13.6% | 3.08 | -2.6% | -3.2% | +2.0% | -1.0% | +3.0% | -1.0% | — |
| Nov 12, 2024 | AMC | -0.19 | -0.24 | -26.3% | 3.64 | +2.5% | -13.7% | -3.8% | -6.0% | -2.5% | -1.8% | — |
| Aug 14, 2024 | AMC | -0.19 | -0.22 | -15.8% | 3.73 | +0.3% | +11.0% | -3.1% | +4.0% | +1.4% | +2.8% | — |
| May 14, 2024 | AMC | -0.19 | -0.22 | -15.8% | 4.83 | +2.7% | +0.0% | -1.9% | -2.5% | -0.2% | +3.9% | — |
| Mar 21, 2024 | AMC | -0.23 | -0.25 | -8.7% | 5.28 | +0.0% | -6.2% | +2.2% | +3.0% | +6.3% | +2.5% | — |
| Nov 14, 2023 | AMC | -0.23 | -0.24 | -4.3% | 1.40 | -7.1% | +0.0% | -0.7% | +4.3% | +0.7% | -6.8% | — |
| Aug 14, 2023 | AMC | -0.24 | -0.27 | -12.5% | 1.77 | +1.1% | -7.3% | -2.4% | +3.8% | +1.2% | -0.6% | — |
| May 15, 2023 | AMC | -0.24 | -0.26 | -8.3% | 1.28 | +5.5% | -8.6% | +3.0% | -2.1% | +17.8% | +30.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 4 | Leerink Partners | Initiates | Outperform | $12 | $5.94 | $5.99 | +0.8% | +23.6% | -12.8% | +2.3% | +4.3% | -6.6% |
| May 28 | BTIG Research | Initiates | Buy | $9 | $5.16 | $5.25 | +1.7% | +17.8% | +11.0% | -3.4% | -2.6% | -6.5% |
| Mar 30 | Needham | Maintains | Buy → Buy | — | $2.78 | $2.75 | -1.1% | -0.7% | +8.7% | +5.0% | -2.9% | -3.3% |
| Mar 25 | Needham | Maintains | Buy → Buy | — | $3.01 | $2.90 | -3.7% | -3.0% | -1.4% | -3.5% | -0.7% | +8.7% |
| Mar 18 | Needham | Maintains | Buy → Buy | — | $3.03 | $2.92 | -3.6% | -5.6% | +7.7% | -3.9% | -1.0% | +2.7% |
| Dec 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.39 | $3.48 | +2.7% | +0.6% | -0.9% | +8.6% | -4.1% | +1.1% |
| Dec 12 | Needham | Maintains | Buy → Buy | — | $3.84 | $3.83 | -0.3% | -5.2% | -6.9% | +4.7% | -4.5% | +0.6% |
| Nov 13 | Needham | Maintains | Buy → Buy | — | $3.40 | $2.98 | -12.4% | -22.4% | +6.8% | +1.4% | -0.7% | +0.7% |
| Aug 18 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.93 | $2.90 | -1.0% | -3.4% | -7.4% | -1.9% | -0.4% | +2.7% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $2.97 | $2.84 | -4.4% | +5.1% | -3.8% | -2.3% | -3.4% | -7.4% |
| Jul 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.89 | $3.04 | +5.2% | +2.8% | -0.7% | -1.0% | -3.1% | +2.5% |
| May 14 | Needham | Maintains | Buy → Buy | — | $2.96 | $3.61 | +22.0% | -1.7% | +1.7% | -2.7% | -3.8% | +0.7% |
| Apr 16 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.12 | $3.11 | -0.3% | -2.2% | +1.3% | -0.6% | +4.6% | -0.6% |
| Apr 9 | Needham | Maintains | Buy → Buy | — | $2.27 | $2.21 | -2.6% | +13.7% | -4.7% | +22.8% | +2.3% | +1.0% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $2.98 | $2.94 | -1.3% | +2.0% | -1.0% | +3.0% | -1.0% | -5.5% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.08 | $3.00 | -2.6% | -3.2% | +2.0% | -1.0% | +3.0% | -1.0% |
| Mar 19 | Needham | Maintains | Buy → Buy | — | $3.08 | $3.00 | -2.6% | -3.2% | +2.0% | -1.0% | +3.0% | -1.0% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.80 | $2.86 | +2.1% | +3.6% | +11.0% | +25.2% | +3.5% | -4.1% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.22 | $3.08 | -4.3% | -11.2% | -0.3% | -4.9% | +5.5% | -2.1% |
| Jan 8 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.07 | $4.09 | +33.2% | +4.9% | -11.2% | -0.3% | -4.9% | +5.5% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.07 | $4.09 | +33.2% | +4.9% | -11.2% | -0.3% | -4.9% | +5.5% |
| Dec 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.68 | $3.73 | +1.4% | +0.5% | +3.5% | -13.1% | -8.7% | -3.9% |
| Dec 3 | Guggenheim | Maintains | Buy → Buy | — | $3.15 | $3.15 | +0.0% | -5.1% | +3.3% | -5.5% | +6.5% | +3.2% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.64 | $3.73 | +2.5% | -13.7% | -3.8% | -6.0% | -2.5% | -1.8% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.73 | $3.74 | +0.3% | +11.0% | -3.1% | +4.0% | +1.4% | +2.8% |
| Jul 11 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.61 | $3.69 | +2.2% | +11.6% | +0.0% | -2.0% | +10.1% | +0.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.83 | $4.96 | +2.7% | +0.0% | -1.9% | -2.5% | -0.2% | +3.9% |
| Mar 26 | Truist | Maintains | Buy → Buy | — | $5.06 | $5.11 | +1.0% | +3.0% | +6.3% | +2.5% | -1.2% | -8.4% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.28 | $5.28 | +0.0% | -6.2% | +2.2% | +3.0% | +6.3% | +2.5% |
| Mar 6 | Truist | Maintains | Buy → Buy | — | $5.26 | $5.70 | +8.4% | +1.9% | -4.3% | -2.1% | -6.4% | +5.1% |
| Mar 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $5.46 | $5.74 | +5.1% | +5.1% | -8.4% | +1.9% | -4.3% | -2.1% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.62 | $3.62 | +0.0% | +15.5% | -1.7% | +7.1% | -6.1% | -3.4% |
| Jan 5 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $3.72 | $3.89 | +4.6% | -2.7% | +15.5% | -1.7% | +7.1% | -6.1% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.40 | $1.30 | -7.1% | +0.0% | -0.7% | +4.3% | +0.7% | -6.8% |
| Aug 16 | Truist | Maintains | Buy → Buy | — | $1.64 | $1.64 | +0.0% | -2.4% | +3.8% | +1.2% | -0.6% | -9.0% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.77 | $1.79 | +1.1% | -7.3% | -2.4% | +3.8% | +1.2% | -0.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.28 | $1.35 | +5.5% | -8.6% | +3.0% | -2.1% | +17.8% | +30.2% |
| May 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $1.28 | $1.35 | +5.5% | -8.6% | +3.0% | -2.1% | +17.8% | +30.2% |
| May 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.25 | $1.31 | +4.8% | +4.8% | +6.1% | +2.2% | -6.7% | -1.1% |
| Aug 12 | TD Cowen | Upgrade | Market Perform → Outperform | — | $4.79 | $5.13 | +7.1% | -0.2% | +1.0% | -5.2% | -5.5% | -2.3% |
| Aug 12 | JP Morgan | Downgrade | Overweight → Underweight | — | $4.79 | $5.13 | +7.1% | -0.2% | +1.0% | -5.2% | -5.5% | -2.3% |
| Aug 12 | Credit Suisse | Maintains | Outperform → Outperform | — | $4.79 | $5.13 | +7.1% | -0.2% | +1.0% | -5.2% | -5.5% | -2.3% |
| Jul 18 | Truist | Maintains | Buy → Buy | — | $3.38 | $3.60 | +6.5% | -0.3% | +6.2% | +1.7% | -1.4% | -6.1% |
| May 31 | Stifel | Maintains | Hold → Hold | — | $3.87 | $3.91 | +1.0% | -5.7% | -3.6% | +9.4% | -5.5% | -7.7% |
| Mar 23 | Credit Suisse | Maintains | Outperform → Outperform | — | $7.48 | $7.45 | -0.4% | +0.7% | +10.6% | -7.6% | -1.4% | +10.8% |
| Feb 1 | Berenberg | Maintains | Buy → Buy | — | $6.73 | $7.05 | +4.8% | +7.6% | +1.9% | -5.7% | +3.4% | +2.5% |
| Nov 10 | BofA Securities | Downgrade | Neutral → Underperform | — | $14.23 | $13.21 | -7.2% | -9.4% | +0.5% | -13.7% | +1.3% | +6.5% |
| Aug 16 | Stifel | Maintains | Hold → Hold | — | $25.01 | $24.50 | -2.0% | -15.7% | -7.5% | +5.2% | -0.1% | +9.9% |
| Aug 16 | TD Cowen | Maintains | Market Perform → Perform | — | $25.01 | $24.50 | -2.0% | -15.7% | -7.5% | +5.2% | -0.1% | +9.9% |
| Aug 16 | Credit Suisse | Maintains | Outperform → Outperform | — | $25.01 | $24.50 | -2.0% | -15.7% | -7.5% | +5.2% | -0.1% | +9.9% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | Pangalos Menelas NDir | — | Buy | 37,453 | $5.36 | $201K | 232,308 | +4.53% | +6.91% |
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Absci's rapid progression of AI-designed ABS-201 into human trials with positive safety signals validates its platform technology, potentially justifying higher valuations if clinical efficacy data continues to impress investors.
Mar 24
8-K · 5.02
!!! Very High
Absci Corporation -- 8-K 5.02: Executive Change
Absci Corporation will lose director Andreas Busch on March 31, 2026, potentially affecting board oversight and decision-making capabilities.
Mar 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Fmr Llc | 22,550,997 | $68M | Added | Mar 2026 |
| 2 | Ark Investment Management Llc | 13,726,169 | $41M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 5,886,640 | $18M | New | Mar 2026 |
| 4 | Advanced Micro Devices Inc | 5,714,285 | $17M | — | Mar 2026 |
| 5 | Morgan Stanley | 2,957,676 | $10M | Added | Dec 2025 |
| 6 | Woodline Partners Lp | 3,300,169 | $10M | Added | Mar 2026 |
| 7 | Two Sigma Investments, Lp | 2,898,766 | $9M | Added | Mar 2026 |
| 8 | Gem Investment Advisors, Llc | 2,170,863 | $7M | — | Mar 2026 |
| 9 | Ubs Group Ag | 1,599,809 | $5M | Reduced | Mar 2026 |
| 10 | Marshall Wace, Llp | 1,219,052 | $4M | New | Mar 2026 |
| 11 | Millennium Management | 1,197,369 | $4M | Added | Mar 2026 |
| 12 | Northern Trust Corp | 1,023,408 | $3M | Added | Mar 2026 |
| 13 | Vanguard Fiduciary Trust Co | 951,446 | $3M | New | Mar 2026 |
| 14 | Vanguard Portfolio Management Llc | 801,063 | $2M | New | Mar 2026 |
| 15 | Aqr Capital Management Llc | 699,439 | $2M | Added | Mar 2026 |
| 16 | D.e. Shaw & Co | 649,817 | $2M | New | Mar 2026 |
| 17 | Susquehanna International Group, Llp | 647,878 | $2M | Added | Mar 2026 |
| 18 | Iq Eq Fund Management (Ireland) Ltd | 470,386 | $2M | Added | Dec 2025 |
| 19 | Bank Of America Corp /de/ | 487,193 | $1M | Added | Mar 2026 |
| 20 | Citadel Advisors Llc | 404,423 | $1M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.16B
Enterprise Value
$872.7M
P/E (TTM)
-8.82x
Forward P/E
—
PEG Ratio
0.39x
P/B
5.35x
P/S
361.97x
P/FCF
-10.78x
EV/EBITDA
—
Shares Out
136.8M
Financials (TTM)
Revenue
$2.8M
Net Income
-$115.2M
EBITDA
-$113.0M
Free Cash Flow
-$94.0M
Op Cash Flow
-$92.9M
EPS Basic
$-0.84
EPS Diluted
$-0.84
EPS Forward
$-0.79
Gross Margin
-319.4%
Op Margin
-4454.2%
Net Margin
-4113.7%
Balance Sheet
Total Assets
$216.3M
Total Liab.
$26.8M
Total Equity
$189.4M
Cash
$144.3M
LT Debt
$3.5M
Book Value/Sh
$1.39
Debt/Equity
0.03x
Current Ratio
6.57
Quick Ratio
6.57
Returns & Growth
ROE
-60.8%
ROA
-53.2%
ROIC
-63.6%
Rev Growth YoY
-38.2%
EPS Growth YoY
+10.6%
Price Returns
2W
+21.8%
1M
+35.8%
3M
+146.4%
6M
+112.9%
12M
+154.7%
Technicals
52W High
$8.17
52W Low
$2.24
50d MA
$5.29
200d MA
$3.71
RSI (14)
55.90
ATR (14)
$0.71
Beta
2.01
Avg Volume
5.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$6.16
High
$8.00
Low
$4.32
Median
$6.16
Data updated apr 24, 2026 10:17am
· Source: financialmodelingprep.com